News: Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,847.00GBp
6:06am EDT
Price Change (% chg)

97.00p (+2.59%)
Prev Close
3,750.00p
Open
3,766.00p
Day's High
3,871.00p
Day's Low
3,741.00p
Volume
1,682,135
Avg. Vol
3,120,793
52-wk High
5,470.00p
52-wk Low
2,457.00p

Search Stocks
Select another date:

Deals of the day- Mergers and acquisitions

Oct 21 - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:

Britain's FTSE 100 rebounds, GKN gains after results

LONDON, Oct 21 - Britain's top share index rose on Tuesday, with gains for engineering firm GKN after results and in drugmaker Shire on merger speculation supporting the broader market.

CORRECTED-AbbVie CEO Gonzalez loses Shire, but wins praise for gusty move

NEW YORK, Oct 20 - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker.

AbbVie CEO Gonzales loses Shire, but wins praise for gutsy move

NEW YORK - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker.

AbbVie says $55 billion acquisition of Shire officially dead

- U.S. drugmaker AbbVie Inc said on Monday it has reached agreement with Shire Plc to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away from the deal.

UPDATE 1-AbbVie says $55 billion acquisition of Shire officially dead

(Adds CEO comment, background, share repurchase, share price)

AbbVie says $55 billion acquisition of Shire officially dead

Oct 20 - U.S. drugmaker AbbVie Inc said on Monday it has reached agreement with Shire Plc to officially call off its proposed $55 billion purchase of the Irish company, and will pay Shire a $1.64 billion breakup fee for walking away from the deal.

Top Allergan holder Paulson urges deal with Shire: sources

- Allergan Inc shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc , according to two people familiar with the matter.

UPDATE 2-Top Allergan holder Paulson urges deal with Shire -sources

(Adds details on Paulson shareholdings in Allergan and Shire, background)

REFILE-UPDATE 1-Shire CFO to leave drugmaker as AbbVie drops bid

LONDON, Oct 20 - British drugmaker Shire will lose its interim chief financial officer early next year to water supplier Severn Trent, the latest blow for Shire, whose proposed $55-billion acquisition by U.S. rival AbbVie was aborted last week.

Select another date:
Search Stocks